Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
APGAR ScoreAssisted Delivery (FIGO)BPP (Manning Score)Bishop ScoreCARPREG II Cardiac RiskCervical Cancer StagingContraceptive Pearl IndexDoppler Matrix (UA/MCA)EFW (Hadlock)Endometrial StagingEndometrial ThicknessFGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey ScoreFetal Anemia (MCA PSV)GDM Diagnostic CriteriaGPA History IndicatorGail Model Breast RiskGestational Dating (LMP)HIV PMTCT ProtocolIOTA Simple RulesIVF Due Date & AMHIron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS ClassificationOvarian Cancer StagingPAS Hemorrhage RiskPPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS CriteriaSyphilis ManagementTORCH FrameworkVBAC Success ProbabilityVulvar Cancer StagingWeight Gain (IOM)mWHO Cardiac Risk
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2026

•

All Rights Reserved

Gail Model Breast Risk

Gail Model Breast Risk

Breast Cancer Risk Assessment Tool (BCRAT)

Note: The Gail Model is most accurate for women over 35 without a personal history of LCIS or DCIS. A 5-year risk ≥ 1.67% is considered "high risk" and may justify chemoprevention.

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

Primary Clinical Uses

Estimating the 5-year and lifetime risk of developing invasive breast cancer in women aged 35 years and older.
Determining eligibility for prophylactic breast cancer risk-reducing medications (Tamoxifen/Raloxifene).
Triaging patients for enhanced screening protocols (e.g., adjunctive Breast MRI).

Exclusion Criteria

This tool is useless and invalid for patients with known BRCA1/BRCA2 genetic mutations, patients with a history of Lobular/Ductal Carcinoma In Situ (LCIS/DCIS), or those who have received prior medical radiation to the chest.

How it Works

The Required Variables

Current Age of the patient.
Age at menarche (earlier is higher estrogen exposure risk).
Age at the time of first live birth (or nulliparity; older age is higher risk).
Number of first-degree female relatives (mother, sister, daughter) with breast cancer.
Number of previous benign breast biopsies.
Presence of Atypical Hyperplasia explicitly confirmed on a prior biopsy.

Scoring Threshold

5-Year Risk ≥ 1.67%Considered "High Risk". Chemoprevention discussion indicated.
5-Year Risk < 1.67%Standard screening protocols.

Clinical Pearls

Model Limitations

The Gail Model only considers FIRST-degree relatives. It entirely ignores paternal history, second-degree relatives, and the age of onset of cancer in those relatives.
Calculates the risk of INVASIVE breast cancer only, completely stripping out the risk for developing non-invasive in-situ ductal disease.
African American and Hispanic populations historically had their risks underestimated until subsequent mathematical calibrations were added; always utilize an ethnicity-adjusted version if available.

Next Steps

Actionable Chemoprevention

01
If 5-Year risk exceeds 1.67%, initiate a shared-decision making discussion regarding SERMs (Selective Estrogen Receptor Modulators).
02
Premenopausal High Risk: Consider Tamoxifen for 5 years.
03
Postmenopausal High Risk: Consider Tamoxifen, Raloxifene, or Aromatase Inhibitors.
04
Caution: SERMs significantly increase the risk of deep vein thrombosis (DVT/PE) and endometrial cancer. Baseline absolute risk must outweigh these side-effects.

The Evidence

The Original Validation

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

Gail MH et al. • J Natl Cancer Inst.. 1989;The massive Breast Cancer Detection Demonstration Project (BCDDP) dataset that established the foundational multivariable logistic regression equation.

Origins & History

Dr. Mitchell Gail

Dr. Mitchell Gail introduced this algorithm to specifically help clinical trial managers identify high-risk women who were mathematically optimal for inclusion in the landmark Breast Cancer Prevention Trial (BCPT), ensuring enough statistical power could be reached.

Last Comprehensive Review: 2026-07-17

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.